Trial Profile
A Phase II Trial of Daily Low-Dose Interleukin-2 (IL-2) for Steroid-Refractory Chronic Graft-Versus-Host-Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2023
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Prednisone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 08 Mar 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 31 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 12 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.